scholarly journals Tigecycline application in a 3-month-old infant with multiple drug resistant Klebsiella pneumonia: a case report

Gut Pathogens ◽  
2018 ◽  
Vol 10 (1) ◽  
Author(s):  
Cheng Peng ◽  
Xiaofeng Wang ◽  
Jiangwei Zhang ◽  
Yi Jiang ◽  
Xinlin Hou
Keyword(s):  
Case Report ◽  
Multiple Drug ◽  
Klebsiella Pneumonia ◽  
Drug Resistant ◽  
Multiple Drug Resistant

scholarly journals Neurodevelopment Outcome of Neonates Treated With Intraventricular Colistin for Ventriculitis Caused by Multiple Drug-Resistant Pathogens—A Case Series

2021 ◽  
Vol 8 ◽  
Author(s):  
Kashif Hussain ◽  
Muhammad Sohail Salat ◽  
Gul Ambreen ◽  
Javaid Iqbal
Keyword(s):  
Blood Brain Barrier ◽  
Case Series ◽  
Brain Barrier ◽  
Multiple Drug ◽  
Klebsiella Pneumonia ◽  
Drug Resistant ◽  
Neurodevelopmental Outcomes ◽  
Average Birth Weight ◽  
Blood Brain ◽  
Multiple Drug Resistant

Background: Multiple-drug-resistant Gram-negative bacteria (MDR-GNB)-associated neonatal ventriculitis is a life-threatening complication that needs timely diagnosis and effective treatment with broad-spectrum antimicrobials in critical-care settings. Inadequate penetration of antibiotics through the blood–brain barrier also demands an intraventricular (IVT) route of administration. This study reports mortality and neurodevelopmental sequelae of neonates till 18 months of age, who received IVT-colistin for treating MDR-GNB associated ventriculitis.Methods: In a case series of seven neonates with ventriculitis due to MDR-GNB at NICU of Aga Khan University Hospital, Pakistan, between June 2015 and 2018, we reviewed IVT-colistin therapy in critically ill neonates. Treatment outcomes were assessed based on clinical sign's resolution and MDR-GNB eradication in subsequent CSF cultures. Neurodevelopmental outcomes were evaluated at 18 months after discharge.Results: The average birth weight was 1.38 kg (range: 1.02–1.5 kg), and the average gestational age was 30.7 weeks (ranged: 26–34 weeks). All neonates reported colistin-sensitive MDR-GNB in CSF, five with Acinetobacter baumannii, and polymicrobial CNS infection was found in two patients (one due to Klebsiella pneumonia and A. baumannii and one due to K. pneumonia and Escherichia coli). All neonates received IVT colistin and concomitant intravenous meropenem, and five of them also received intravenous colistin. One neonate died. At the 18-month assessment, only one neonate had cerebral palsy and hydrocephaly and 50% had seizure disorders.Conclusion: Practicing intraventricular antibiotics in the neonatal population is challenging but may be used successfully, especially to overcome the limitation of poor penetration through the blood–brain barrier.

scholarly journals OTOTOXICITY IN MDR-TB PATIENTS ON CATEGORY-4 REGIMEN: A CASE REPORT

2020 ◽  
Vol 7 (2) ◽  
pp. 257-259
Author(s):  
Tanish Baqar ◽  
Sharique Ahmad ◽  
Silky Rai
Keyword(s):  
Case Report ◽  
Large Scale ◽  
Multiple Drug Resistance ◽  
Multiple Drug ◽  
Drug Resistant ◽  
Drug Resistant Tuberculosis ◽  
Medical Progress ◽  
Resistant Tuberculosis ◽  
Multiple Drug Resistant ◽  
Mdr Tb

Multiple drug-resistant tuberculosis (MDR-TB) is a critical situation affecting adults as properly as children across the globe (1). To determine the incidence and risk factors associated with Multiple Drug Resistant Tuberculosis (MDR-TB) (2), we studied Ototoxicity on 18 culture confirmed MDR-TB patients in Eras' Lucknow Medical College and Hospital, Lucknow from September, 2019 to January, 2020. This case follows a well documented report of a patient describing an unusual and novel occurrence of ototoxicity when undergoing treatment concerning multiple drug resistance tuberculosis along with symptoms, signs, diagnosis, treatment and follow-up (3). For descriptive convenience, the patient will be classified as patient 1. The following case is the cornerstones of medical progress and provides many new ideas in medicine. Containing an extensive review of the relevant literature on the topic, the case report is a rapid short communication between busy clinicians who may not have time or resources to conduct large scale research.(4)

scholarly journals trans-Translation inhibitors bind to a novel site on the ribosome and clear Neisseria gonorrhoeae in vivo

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Zachary D. Aron ◽  
Atousa Mehrani ◽  
Eric D. Hoffer ◽  
Kristie L. Connolly ◽  
Pooja Srinivas ◽  
...  
Keyword(s):  
Oral Dose ◽  
Neisseria Gonorrhoeae ◽  
Multiple Drug ◽  
Specific Inhibition ◽  
Drug Resistant ◽  
Peptidyl Transfer ◽  
Bacterial Ribosome ◽  
Multiple Drug Resistant ◽  
Unique Site

AbstractBacterial ribosome rescue pathways that remove ribosomes stalled on mRNAs during translation have been proposed as novel antibiotic targets because they are essential in bacteria and are not conserved in humans. We previously reported the discovery of a family of acylaminooxadiazoles that selectively inhibit trans-translation, the main ribosome rescue pathway in bacteria. Here, we report optimization of the pharmacokinetic and antibiotic properties of the acylaminooxadiazoles, producing MBX-4132, which clears multiple-drug resistant Neisseria gonorrhoeae infection in mice after a single oral dose. Single particle cryogenic-EM studies of non-stop ribosomes show that acylaminooxadiazoles bind to a unique site near the peptidyl-transfer center and significantly alter the conformation of ribosomal protein bL27, suggesting a novel mechanism for specific inhibition of trans-translation by these molecules. These results show that trans-translation is a viable therapeutic target and reveal a new conformation within the bacterial ribosome that may be critical for ribosome rescue pathways.

Sign in / Sign up

Export Citation Format

Share Document